Preclinical and clinical activity of sunitinib in patients with cisplatin-refractory or multiply relapsed germ cell tumors: a Canadian Urologic Oncology Group/German Testicular Cancer Study Group cooperative study.
暂无分享,去创建一个
C. Bokemeyer | K. Oechsle | F. Mayer | C. Kollmannsberger | E. Winquist | F. Honecker | K. Chi | L. Wood | T. Cheng | M. Fenner | P. Czaykowski | J. Hartmann | S. Glaesener | J. Hartmann | Carsten Bokemeyer | Frank Mayer | Kim N. Chi | C. Kollmannsberger | Lori Wood | Karin Oechsle | Piotr Czaykowski | Martin Fenner
[1] G. Sonpavde,et al. Phase II study of gemcitabine, cisplatin, and sunitinib (S) in patients with advanced urothelial carcinoma (UC). , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] S. Cheng,et al. Preclinical evaluation of sunitinib as single agent or in combination with chemotherapy in nasopharyngeal carcinoma , 2011, Investigational New Drugs.
[3] G. Suddek. Sunitinib improves chemotherapeutic efficacy and ameliorates cisplatin-induced nephrotoxicity in experimental animals , 2011, Cancer Chemotherapy and Pharmacology.
[4] P. Stephenson,et al. Sunitinib in combination with gemcitabine plus cisplatin for advanced non-small cell lung cancer: a phase I dose-escalation study. , 2010, Lung cancer.
[5] S. Perkins,et al. Phase II study of oxaliplatin (O) and bevacizumab (B) chemotherapy in refractory germ cell tumors (GCT). , 2010 .
[6] C. Bokemeyer,et al. Long term outcome in patients with cisplatin-refractory or multiply relapsed germ cell tumors following treatment with gemcitabine and oxaliplatin {+/-} paclitaxel. , 2010 .
[7] R. Motzer,et al. Phase II trial of sunitinib in patients with relapsed or refractory germ cell tumors , 2010, Investigational New Drugs.
[8] G. Capellá,et al. Sunitinib Inhibits Tumor Growth and Synergizes with Cisplatin in Orthotopic Models of Cisplatin-Sensitive and Cisplatin-Resistant Human Testicular Germ Cell Tumors , 2009, Clinical Cancer Research.
[9] E. Steyerberg,et al. Microsatellite instability, mismatch repair deficiency, and BRAF mutation in treatment-resistant germ cell tumors. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] C. Bokemeyer,et al. Pharmacotherapy of relapsed metastatic testicular cancer , 2008 .
[11] C. Bokemeyer,et al. Comparative proteome, transcriptome, and genome analysis of a gonadal and an extragonadal germ cell tumor cell line. , 2008, Journal of proteome research.
[12] M. Stratton,et al. Somatic KIT mutations occur predominantly in seminoma germ cell tumors and are not predictive of bilateral disease: Report of 220 tumors and review of literature , 2008, Genes, chromosomes & cancer.
[13] V. Grünwald,et al. Targeted therapies for patients with germ cell tumors. , 2008, Expert opinion on investigational drugs.
[14] C. Bokemeyer,et al. Combination chemotherapy with gemcitabine, oxaliplatin, and paclitaxel in patients with cisplatin-refractory or multiply relapsed germ-cell tumors: a study of the German Testicular Cancer Study Group. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[15] O. Potapova,et al. Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248 , 2006, Molecular Cancer Therapeutics.
[16] D. Farmakis,et al. Gemcitabine and oxaliplatin (GEMOX) in patients with cisplatin-refractory germ cell tumors: a phase II study. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.
[17] Paul M. Schneider,et al. High-Throughput Analysis of Genome-Wide Receptor Tyrosine Kinase Expression in Human Cancers Identifies Potential Novel Drug Targets , 2004, Clinical Cancer Research.
[18] O. Cummings,et al. KIT mutations are common in testicular seminomas. , 2004, The American journal of pathology.
[19] C. Bokemeyer,et al. Combination chemotherapy with gemcitabine plus oxaliplatin in patients with intensively pretreated or refractory germ cell cancer: a study of the German Testicular Cancer Study Group. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] M. Hofmann,et al. Low dose carboplatin combined with angiostatic agents prevents metastasis in human testicular germ cell tumor xenografts. , 2003, The Journal of urology.
[21] P. Albers,et al. Angiogenetic protooncogene ets-1 induced neovascularization is involved in the metastatic process of testicular germ cell tumors. , 2003, European urology.
[22] N. Pryer,et al. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. , 2003, Molecular cancer therapeutics.
[23] J. Binder,et al. Serum levels of basic fibroblast growth factor reflect disseminated disease in patients with testicular germ cell tumors , 2003, Urological Research.
[24] C. Bokemeyer,et al. Activity of oxaliplatin in patients with relapsed or cisplatin-refractory germ cell cancer: a study of the German Testicular Cancer Study Group. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] P. Catalano,et al. Phase II study of paclitaxel plus gemcitabine in refractory germ cell tumors (E9897): a trial of the Eastern Cooperative Oncology Group. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] L. Einhorn,et al. Results of treatment after relapse from high-dose chemotherapy in germ cell tumors. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] M. van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.
[28] M Van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.
[29] S. Akiba,et al. Expression of vascular endothelial growth factor in patients with testicular germ cell tumors as an indicator of metastatic disease , 1999, Cancer.
[30] C. Bokemeyer,et al. Gemcitabine in patients with relapsed or cisplatin-refractory testicular cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] S. Williams,et al. Phase II trial of gemcitabine in refractory germ cell tumors. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] A Kramar,et al. High-dose chemotherapy as salvage treatment in germ cell tumors: a multivariate analysis of prognostic variables. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] G. Viglietto,et al. Neovascularization in human germ cell tumors correlates with a marked increase in the expression of the vascular endothelial growth factor but not the placenta-derived growth factor. , 1996, Oncogene.
[34] L. Schwartz,et al. Phase II trial of paclitaxel shows antitumor activity in patients with previously treated germ cell tumors. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] L. Einhorn,et al. Phase II study of daily oral etoposide in refractory germ cell tumors. , 1990, Seminars in oncology.
[36] G. Tricot,et al. Dose-intensive chemotherapy in refractory germ cell cancer--a phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] R. Simon,et al. Optimal two-stage designs for phase II clinical trials. , 1989, Controlled clinical trials.
[38] S. Hirohashi,et al. Four new human germ cell tumor cell lines. , 1988, Laboratory investigation; a journal of technical methods and pathology.
[39] P. Andrews. Retinoic acid induces neuronal differentiation of a cloned human embryonal carcinoma cell line in vitro. , 1984, Developmental biology.